FREE CE: Severe Pediatric Asthma Treatment Strategies

Up to 5% of the 5.5 million children with asthma in the United States have uncontrolled and/or severe disease, leaving them at risk for life-threatening exacerbations, potentially harmful effects of oral corticosteroid use, and diminished quality of life. Targeted biologic therapies have emerged as safe and effective add-on options for children with severe asthma who are unresponsive to traditional treatments. For optimal outcomes, these children should be referred to a specialist, and a multidisciplinary care approach should be implemented over the longer term.

The second activity in a 2-part series, this program utilizes expert commentary to analyze and contextualize the most current data from the published literature as well as key presentations from recent large medical conferences. The overarching goal of the activity is to provide clinicians who manage the care of children with asthma with up-to-date guidance regarding current research findings and best practices. Earn 0.50 / AMA PRA Category 1 Credit(s)™, 0.50 / AMA PRA Category 1 Credit(s)™/ ABIM MOC Points, or 0.50 / CNE Contact Hour(s).

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Augusta, GA 

Meera R. Gupta, MD, FAAAAI
Associate Professor, Department of Pediatrics
Director, Allergy/Immunology Fellowship Training Program
Section of Immunology, Allergy, and Retrovirology
Texas Children’s Hospital
Baylor College of Medicine
Houston, TX

Eric Schauberger, DO, PhD
Assistant Professor of Pediatrics
Associate Program Director, UW Allergy/Immunology Program
Division of Pediatric Allergy, Immunology and Rheumatology
University of Wisconsin
Madison, WI